The Infinite Prescription: How New York’s Healthcare Leviathan Devours Budgets While Delivering Dubious Health Gains

For thirty years, New York State has poured ever-greater sums into government-sponsored healthcare, primarily through Medicaid and related programs. What was once a targeted safety net has metastasized into an open-ended entitlement machine. How much "healthcare" is required or warranted for the average citizen? The answer to that question appears to be "more".

The data reveals a stark pattern: costs have exploded, enrollment has ballooned, yet measurable improvements in population health remain elusive or marginal. This is not an accident. It is the predictable outcome of a system that severs consumption from cost, framed by politicians as an ethical imperative with no limiting principle. The true beneficiaries? Pharma giants, healthcare conglomerates, and the elected officials sustained by their largesse. The victims? Taxpayers and a public fed illusions of boundless benevolence.

Let us confront the numbers, drawn from public records like CMS reports, state budget documents, and health department data. In the mid-1990s, New York’s total Medicaid spending hovered around $25 billion (state fiscal year 1995-96), with enrollment roughly 3-4 million. By fiscal year 2024, combined federal and state Medicaid spending reached approximately $100 billion, with enrollment averaging over 7 million—about 36% of the state’s population. Including the Essential Plan, publicly subsidized coverage touches nearly 9 million. New York’s per-resident Medicaid spending stands at roughly $4,900 - that is the total state spending on healthcare per person, including people who receive no public benefits. This is the highest in the nation by a wide margin (national average is roughly $2,791).

The NY per-person spend relative to the national average is driven by the higher percentage of our population enrolled in these programs, and the gold-plated versions of these programs which our state officials have chosen to offer our residents.

Total state health-related spending now consumes over 40% of the budget in recent years, crowding out other priorities. Per-enrollee Medicaid costs run high, especially for aged and disabled populations (over $30,000 per enrollee in some categories). Adjusted for inflation and population, both total costs and per-person metrics (per recipient and per resident) have roughly tripled or more over three decades, outpacing general inflation and wage growth.

This is not solely a New York story—it is a national problem amplified here. The U.S. as a whole has seen total health spending rise from roughly $1 trillion in the mid-1990s to over $5.3 trillion today, with per capita figures climbing in tandem. Every state faces pressures from aging populations, expensive new technologies, and third-party payment distortions. However, New York deviates meaningfully: it consistently ranks at or near the top for per-resident Medicaid spending (77% above the national average in recent federal data), per capita personal health expenditures, and Medicaid’s share of the state budget. While national trends show similar cost drivers, New York’s combination of generous eligibility, rich benefits (especially long-term care), high provider payments, and the regulatory environment has pushed its trajectory higher and faster in key metrics. The gap has not narrowed; in many comparisons, it has held or grown.

Why this explosion? Healthcare is not a finite good like food or the number of bricks required to build a house. Healthcare is potentially infinite. Each of us could consume endless doctor visits, MRIs, batteries of tests, novel drugs, advanced imaging, preventive gadgets, and experimental therapies. There is always one more scan, one more prescription, one more specialist. When government removes the consumer’s direct cost-benefit calculus—making services “free” at the point of use—demand surges toward infinity. Why not demand an MRI for a twisted ankle if it costs you nothing? Private markets discipline this through prices and trade-offs; third-party payers, especially government ones, do not.

Politicians evade this reality with ethical theater. Is it “right” to withhold any conceivable beneficial service? They pose the question as if resources are limitless and trade-offs nonexistent. Yet daily full-body diagnostics for every citizen would indeed yield marginal health gains for some—at infinite cost. No rational individual budgets their own life this way. The state, insulated from market signals, effectively endorses the infinite path. This framing voids any “line in the sand,” turning healthcare into a bottomless fiscal pit.

The results are predictable and visible in the ledgers. Spending has skyrocketed as a share of the state budget (now dominating alongside education). Per-recipient and per-resident costs have climbed relentlessly. Enrollment growth, accelerated by ACA expansions and pandemic policies, has far outstripped population growth. Who profits? Pharmaceutical companies peddling ever-costlier drugs, hospital systems and providers expanding facilities and technologies, and the political class they fund. Lobbying flows, campaign contributions, and revolving doors ensure the spigot stays open.

Now, the crucial question: what benefits have New Yorkers reaped in actual health? Life expectancy has risen from around 75-77 years in the mid-1990s to roughly 80-82 years recently (with NYC rebounding post-COVID to 82.6 in 2023). This tracks national trends driven more by lifestyle shifts decades earlier than by recent spending surges. Yet chronic conditions persist or worsen. Diabetes prevalence has climbed significantly—national adult rates doubled or more since the 1990s, with New York mirroring or exceeding trends (around 10-12% diagnosed in recent BRFSS data, higher in certain demographics). Obesity, heart disease precursors, and other indicators show limited reversal despite trillions nationally and billions locally.

Importantly, spending correlates poorly with outcomes once basic coverage is achieved. New York’s outsized per-capita investment yields results comparable to lower-spending states or nations, adjusted for demographics. Gains appear front-loaded historically; marginal dollars buy diminishing returns amid administrative bloat, defensive medicine, and induced demand. The population is not markedly healthier in proportion to the tripling of real costs. Instead, we subsidize volume: more procedures, higher-priced innovations, without commensurate mortality or morbidity drops attributable to the expansions.

This is the disaster. Skyrocketing costs burden taxpayers and distort the economy, with little proven aggregate health dividend beyond what targeted, efficient aid might achieve. The system enriches concentrated interests—pharma execs, provider lobbies, and politicians who virtue-signal while expanding the patronage. Elites control the narrative: question the spending, and you are accused of cruelty. Yet true compassion demands accountability—finite resources, real trade-offs, consumer skin in the game.

New Yorkers deserve more from our political class. Demand leaders who impose limits, incentivize efficiency, and reject the infinite prescription. Reject the cynicism of a machine that grows itself under ethical camouflage. Understand the universe of incentives: when cost decouples from benefit, consumption knows no bound, and power accrues to those dispensing the unbound. The electorate can still choose restraint over illusion—before the ledger collapses under its own weight.